Loading
A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Genzyme, a Sanofi Company, completed.
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen is a phase 3 interventional study registered as NCT00295763 by Genzyme, a Sanofi Company, with 61 participants recorded, started 2006-05 and reaching its primary completion in 2006-07. Interventions recorded: Thyrogen (thyrotropin alfa for injection). Conditions recorded: Differentiated Thyroid Cancer.
Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.